$-0.17 EPS Expected for Assertio Therapeutics, Inc. (ASRT)

October 13, 2018 - By Adrian Erickson

Analysts expect Assertio Therapeutics, Inc. (NASDAQ:ASRT) to report $-0.17 EPS on November, 6.They anticipate $0.08 EPS change or 32.00 % from last quarter’s $-0.25 EPS. After having $-0.33 EPS previously, Assertio Therapeutics, Inc.’s analysts see -48.48 % EPS growth. The stock increased 2.41% or $0.13 during the last trading session, reaching $5.52. About 305,798 shares traded. Assertio Therapeutics, Inc. (NASDAQ:ASRT) has declined 9.24% since October 13, 2017 and is downtrending. It has underperformed by 24.86% the S&P500.

Assertio Therapeutics, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. The company has market cap of $352.82 million. It offers Gralise , an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. It currently has negative earnings. The firm also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>